Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft für klinische spezialpräparate mbh - melphalan - powder and solvent for solution for injection/infusion - 50 milligram(s) - melphalan

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - terbinafine hydrochloride - cutaneous cream - 10mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - terbinafine hydrochloride - cutaneous cream - 10mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - terbinafine hydrochloride - cutaneous cream - 10mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - terbinafine hydrochloride - cutaneous cream - 10mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

niche generics ltd - terbinafine hydrochloride - cutaneous cream - 10mg/1gram

Malta - English - Medicines Authority

farco-pharma pharmazeutische praparate gmbh gereonsmühlengasse 1 - 11, 50670 köln, germany - chlorhexidine digluconate, methyl hydroxybenzoate, lidocaine hydrochloride, propyl hydroxybenzoate - gel - chlorhexidine digluconate 52.3 mg methyl hydroxybenzoate 62.7 mg lidocaine hydrochloride 2090 mg propyl hydroxybenzoate 26.1 mg - anesthetics

European Union - English - EMA (European Medicines Agency)

photonamic gmbh & co. kg - 5-aminolevulinic acid hydrochloride - glioma - antineoplastic agents - gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (world health organization grade iii and iv).

European Union - English - EMA (European Medicines Agency)

medac - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; leukemia, myelogenous, chronic, bcr-abl positive; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome - protein kinase inhibitors - imatinib medac is indicated for the treatment of:paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;paediatric patients with ph+cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase;adult and paediatric patients with ph+cml in blast crisis;adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+all) integrated with chemotherapy;adult patients with relapsed or refractory ph+all as monotherapy;adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement;adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery.the effect of imatinib on the outcome of bone marrow transplantation has not been determined.in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp.the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited. except in newly diagnosed chronic phase cml, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - treosulfan - oral capsule - 250mg